Sarepta Therapeutics Inc (SRPT) Receives $65.52 Average PT from Analysts

Shares of Sarepta Therapeutics Inc (NASDAQ:SRPT) have been given a consensus recommendation of “Buy” by the twenty-five ratings firms that are currently covering the firm, Marketbeat.com reports. Two research analysts have rated the stock with a sell recommendation, five have given a hold recommendation and seventeen have assigned a buy recommendation to the company. The average 1 year price target among brokerages that have covered the stock in the last year is $65.52.

Several equities research analysts recently issued reports on SRPT shares. Goldman Sachs Group reiterated a “buy” rating and issued a $71.00 price target on shares of Sarepta Therapeutics in a research note on Friday, October 6th. ValuEngine cut Sarepta Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, October 2nd. Janney Montgomery Scott initiated coverage on Sarepta Therapeutics in a research note on Wednesday, January 3rd. They set a “buy” rating and a $75.00 target price for the company. Oppenheimer restated a “buy” rating on shares of Sarepta Therapeutics in a research note on Monday, September 25th. Finally, BidaskClub upgraded Sarepta Therapeutics from a “hold” rating to a “buy” rating in a research note on Monday, December 25th.

In other news, CEO Douglas S. Ingram purchased 38,138 shares of the business’s stock in a transaction on Wednesday, November 8th. The shares were acquired at an average price of $52.44 per share, with a total value of $1,999,956.72. Following the completion of the transaction, the chief executive officer now owns 420,196 shares of the company’s stock, valued at approximately $22,035,078.24. The purchase was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Hans Lennart Rudolf Wigzell sold 6,667 shares of the company’s stock in a transaction on Thursday, November 30th. The shares were sold at an average price of $55.89, for a total transaction of $372,618.63. Following the sale, the director now directly owns 13,333 shares in the company, valued at approximately $745,181.37. The disclosure for this sale can be found here. Corporate insiders own 9.60% of the company’s stock.

Several hedge funds have recently added to or reduced their stakes in the company. Ameritas Investment Partners Inc. boosted its position in shares of Sarepta Therapeutics by 6.3% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 4,561 shares of the biotechnology company’s stock worth $154,000 after purchasing an additional 271 shares in the last quarter. Advisor Group Inc. boosted its position in shares of Sarepta Therapeutics by 3.2% during the 2nd quarter. Advisor Group Inc. now owns 10,402 shares of the biotechnology company’s stock worth $351,000 after purchasing an additional 326 shares in the last quarter. Legal & General Group Plc boosted its position in shares of Sarepta Therapeutics by 3.9% during the 2nd quarter. Legal & General Group Plc now owns 17,590 shares of the biotechnology company’s stock worth $593,000 after purchasing an additional 663 shares in the last quarter. Parametric Portfolio Associates LLC boosted its position in shares of Sarepta Therapeutics by 0.8% during the 2nd quarter. Parametric Portfolio Associates LLC now owns 109,852 shares of the biotechnology company’s stock worth $3,703,000 after purchasing an additional 818 shares in the last quarter. Finally, C WorldWide Group Holding A S lifted its position in Sarepta Therapeutics by 0.8% in the 3rd quarter. C WorldWide Group Holding A S now owns 122,469 shares of the biotechnology company’s stock valued at $5,555,000 after acquiring an additional 941 shares in the last quarter. 82.02% of the stock is currently owned by institutional investors.

Shares of Sarepta Therapeutics (NASDAQ SRPT) traded down $0.15 during mid-day trading on Monday, hitting $58.99. The company had a trading volume of 1,632,325 shares, compared to its average volume of 2,409,646. The company has a current ratio of 10.44, a quick ratio of 9.52 and a debt-to-equity ratio of 0.04. The company has a market capitalization of $3,810.00, a PE ratio of -28.92 and a beta of 1.37. Sarepta Therapeutics has a fifty-two week low of $26.26 and a fifty-two week high of $60.22.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings results on Wednesday, October 25th. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.86) by $0.66. The business had revenue of $45.95 million during the quarter, compared to analysts’ expectations of $41.29 million. Sarepta Therapeutics had a negative return on equity of 51.72% and a negative net margin of 112.08%. During the same period in the previous year, the company posted ($0.95) earnings per share. equities research analysts predict that Sarepta Therapeutics will post -3.07 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This report was first reported by Markets Daily and is owned by of Markets Daily. If you are reading this report on another site, it was copied illegally and reposted in violation of United States & international trademark & copyright laws. The correct version of this report can be viewed at https://www.themarketsdaily.com/2018/01/11/sarepta-therapeutics-inc-srpt-receives-65-52-average-pt-from-analysts.html.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).

Analyst Recommendations for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply